News / Health

India's Cancer-Drug Ruling Likely to Have Global Impact

People gather at Novartis India headquarters in Mumbai April 1, 2013.
People gather at Novartis India headquarters in Mumbai April 1, 2013.
Jessica Berman
A landmark ruling by India’s high court this week struck down a bid by Swiss drugmaker Novartis to extend patent protection for its cancer drug, Glivec.

The decision is seen as a blow to Western pharmaceutical companies seeking to protect their financial interests.  Experts say it could embolden pharmaceutical companies in other countries hoping to produce generic versions of name-brand medications.  That could mean wider availability of the less expensive drugs throughout the developing world.

India is not the only country manufacturing generic versions of important and popular drugs.  Argentina and the Philippines have passed strict laws limiting the patent protections on name-brand drugs developed by U.S. and European pharmaceutical companies, including medications to treat HIV, the virus that causes AIDS.
 
Patents allow companies that develop a drug to maintain exclusive rights to sell it at a higher price for an extended period of time, in order to recoup their research and development costs.  Western pharmaceutical firms say those returns are essential to their ability to develop new and better medicines.

In the India case, which has been wending its way through the country’s judicial system for 7 years, Novartis failed to convince the high court that it had made changes to Glivec, its widely used leukemia drug, significant enough to warrant extending its patent and exclusive marketing rights.

Tahir Amin is a director of the New York-based Initiative for Medicines, Access and Knowledge, a non-profit organization which works on patent cases to increase access to drugs.  Amin says the India case is likely to have far-reaching implications.

“Globally, I think a number of countries will look at this and say, “Well India stood its ground,” and will also realize that actually if India is standing its ground, even though it has a stronger geopolitical standing and can actually probably stand up to the U.S. and Europe a little bit more, I think other countries will also take notice of this and say, 'This is in our public interest and health interest to adopt patent laws that are somewhat similar,'” said Amin.

India exports some $10 billion worth of generic drugs every year and, along with China, produces about 80 percent of the ingredients that are used in the manufacture of drugs in the United States. India also produces generic versions of many popular drugs.

Novartis and other drug companies say the Indian court ruling may force them to pull their research dollars out of India.

Mark Grayson is a spokesman for the Pharmaceutical Research and Manufacturers of America, or PhRMA, which represents drug manufacturers.
 
“We’re disappointed in this ruling because we believe that this just shows a further deteriorating innovation environment in India," said Grayson.

Generic drug versions can be sold at a fraction of the cost of brand-name drugs.  For example, Glivec can cost a patient around $70,000 a year, while the Indian generic versions costs around $2,500.
 
Grayson believes patients who can afford a drug like Glivec should pay full price.

“We believe we need to find ways to get economies that are growing to pay their fair share for the new medicines and the cost that it takes to develop a lot of this medicine," he said.

Grayson says 95 percent of the patients in India who can't afford Glivec can get it for free through a so-called "compassionate care" program run by Novartis.

But Tahir Amin of Initiatives for Medicine says cancer patients have reported that it has been difficult to obtain those free drugs.

“If you are going to be at the whim of philanthropy, then I think most people are not going to get drugs," he said. "And we’ve seen that in other cases as well, where they say we have access programs and so on and so forth.  But only a certain percentage of the population or countries get it.”

But with drug development costs sometimes topping $1 billion, PhRMA’s Grayson fears that India’s patent ruling and others that may follow could slow the pace at which critically needed new drugs come to market.

You May Like

Sydney Hostage-taker Failed to Manipulate Social Media

Gunman forced captives to use personal Facebook, YouTube accounts to issue his demands; online community helped flag messages, urged others not to share them More

UN Seeks $8.4 Billion to Help War-Hit Syrians

Effort aimed at helping Syrians displaced within their own country and those who've fled to neighboring ones More

Who Are the Pakistani Taliban?

It's an umbrella group of militant organizations whose objective is enforcement of Sharia in Pakistan 'whether through peace or war' More

Featured Videos

Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
Putin: Russian Economy to Rebound in 2 Yearsi
X
December 18, 2014 5:13 PM
Russian President Vladimir Putin held his annual end-of-the-year news conference Thursday, tackling questions on the Russian economy, the crisis in Ukraine and Russian relations with the west. VOA's Jeff Custer reports.
Video

Video Putin: Russian Economy to Rebound in 2 Years

Russian President Vladimir Putin held his annual end-of-the-year news conference Thursday, tackling questions on the Russian economy, the crisis in Ukraine and Russian relations with the west. VOA's Jeff Custer reports.
Video

Video Nigerians Fleeing Boko Haram Languish in Camp Near Capital

In its five-year effort to impose Islamic law in northeastern Nigeria, the Boko Haram extremist group has killed thousands of people and forced hundreds of thousands to flee. Some of those who ran for their lives now live in squalor on the edges of the capital, Abuja. Chris Stein reports for VOA.
Video

Video Detained Turkish Journalists Follow Teachings of US-Based Preacher

The Turkish government’s jailing of critical journalists has sparked international condemnation and is being seen as an effort to undermine the followers of an ailing Turkish preacher based in the United States. VOA religion reporter Jerome Socolovsky has more.
Video

Video Will Pakistan School Shooting Galvanize Pakistan Against Extremism?

The attack on a military school in Pakistan’s northwest city of Peshawar left 141 dead, including 132 children. Strong statements of condemnation poured in from across the world. The country announced three days of mourning, and the leadership, both political and military, promised retribution. VOA's Ayesha Tanzeem looks at how likely the Pakistani government is to clamp down on all extremist groups.
Video

Video ‘Anti-Islamization’ Marches Increase Tensions In Germany

Anti-immigrant rallies in Germany have been building in recent weeks, peaking Monday night in the city of Dresden where tens of thousands of people turned out to demonstrate against what they call the ‘Islamization’ of the West. Germany has offered asylum to more Syrian refugees than any other country, and this appears to have set off the protests. Henry Ridgwell reports from London.
Video

Video Aceh Rebuilt Decade After Tsunami, But Scars Remain

On December 26, 2004 there was an earthquake in the Indian Ocean so powerful it caused the Earth’s axis to wobble a few centimeters. Onshore on the island of Sumatra, the resulting tsunami was devastating. A decade later, VOA Correspondent Steve Herman reports from Banda Aceh, Indonesia, where although there is little remaining evidence of the physical devastation, the psychological scars among survivors remain.
Video

Video Refugees Living in Kenya Long for Peace in the Home Countries

Kenya is host to numerous refugees seeking safe haven from conflict. Immigrants from Somalia face challenges in their new lives in Kenya. Ahead of International Migrants Day (December 18) Lenny Ruvaga has more for VOA News from the Kenyan capital.
Video

Video Turkey's Authoritarianism Dismays Western Allies

The Turkish government has been defiant in the face of criticism at home and abroad for its raids targeting opposition media. The European Union on Monday expressed dismay after President Recep Tayyip Erdogan lashed out at Brussels for criticizing his government's action. Turkey's bid to be considered for EU membership has been on hold while critics accuse the NATO ally of increasingly authoritarian rule. Zlatica Hoke reports.

All About America

AppleAndroid